

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Buplex Rx 600 mg film-coated tablets

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 600 mg ibuprofen.

For the full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

Film-coated tablet.

White, oval, biconvex film-coated tablets with a score on one face.

The tablet can be divided into equal doses.

## 4 CLINICAL PARTICULARS

### 4.1 Therapeutic indications

Rheumatic conditions such as arthritic diseases (e.g. rheumatoid arthritis including juvenile rheumatoid arthritis), degenerative arthritic conditions (e.g. osteoarthritis), non-articular rheumatic conditions, other muscular and joint disorders, and soft tissue injuries.

### 4.2 Posology and method of administration

The lowest effective dose should be used for the shortest duration necessary to relieve symptoms (see section 4.4).

The ibuprofen dose depends on the patient's age and body weight. The maximum single dose for adults should not exceed 800 mg of ibuprofen.

#### ***Rheumatic diseases***

##### *Adults:*

The usual dose is 400-600 mg 3 times a day. Maintenance doses of 600 mg-1200 mg daily may be effective in some patients. In acute and severe conditions the dose may be increased to a maximum of 2400 mg in 3 or 4 divided doses.

##### *Adolescents over 12 years of age (>40 kg):*

The recommended dose is 20 mg/kg to a maximum of 40 mg/kg body weight daily in 3 to 4 divided doses. There are other dosage forms which may be more suitable to attain the required posology in this age and body weight group.

#### ***Paediatric population***

This medicine should not be given to children younger than 12 years.

##### *Elderly*

NSAIDs should be used with particular caution in elderly patients who are more prone to adverse events and are at increased risk of potentially fatal gastrointestinal haemorrhage, ulceration or perforation (see section 4.4). If treatment is considered necessary, the lowest dose for the shortest duration necessary to control symptoms should be used. Treatment should be reviewed at regular intervals and discontinued if no benefit is seen or intolerance occurs.

##### *Impaired renal function*

In patients with mild or moderate reduction of renal function, the dose should be kept as low as possible for the shortest duration necessary to control symptoms and renal function monitored. (For patients with severe renal failure see section 4.3).

### *Impaired liver function*

In patients with mild or moderate reduction of liver function the dose should be kept as low as possible for the shortest duration necessary to control symptoms and renal function monitored. (For patients with severe liver failure see section 4.3).

### **Method of administration**

The tablet should be swallowed with a glass of water during or after a meal.

### **4.3 Contraindications**

Ibuprofen is contraindicated in patients with:

- hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- previous hypersensitivity reactions (e.g. asthma, rhinitis, urticaria or angioedema) in response to acetylsalicylic acid or other NSAIDs
- history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy
- active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding)
- severe hepatic or severe renal insufficiency (glomerular filtration below 30 mL/min)
- severe heart failure (NYHA Class IV) or coronary heart disease
- third trimester of pregnancy (see section 4.6)
- significant dehydration (caused by vomiting, diarrhoea or insufficient fluid intake)
- cerebrovascular or other active bleeding
- unclarified blood-formation disturbances

### **4.4 Special warnings and precautions for use**

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2, and GI and cardiovascular risks below). Patients treated with NSAIDs long term should undergo regular medical supervision to monitor for adverse events.

Ibuprofen should only be administered under strict consideration of the benefit-risk ratio in the following conditions:

- Systemic Lupus Erythematosus (SLE) or other autoimmune diseases.
- Congenital disturbance of porphyrin metabolism (e.g. acute intermittent porphyria)
- The first and second trimester of pregnancy
- Lactation

Special care has to be taken in the following cases:

- Gastrointestinal diseases including chronic inflammatory intestinal disease (ulcerative colitis, Crohn's disease)
- Cardiac insufficiency and hypertension
- Reduced renal function
- Hepatic dysfunction
- Disturbed haematopoiesis
- Blood coagulation defects
- Allergies, hay fever, chronic swelling of nasal mucosa, adenoids, chronic obstructive airway disease or bronchial asthma
- Immediately after major surgical interventions

### ***Gastrointestinal safety:***

The use of ibuprofen with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided.

### ***Gastrointestinal bleeding, ulceration and perforation***

GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events.

The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in the elderly. These patients should commence treatment on the lowest dose available.

Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low-dose acetylsalicylic acid, or other medicinal products likely to increase gastrointestinal risk. (See below and section 4.5).

Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.

Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin or heparin, selective serotonin-reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5).

When GI bleeding or ulceration occurs in patients receiving ibuprofen, the treatment should be withdrawn.

NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as their condition may be exacerbated. (See section 4.8).

#### *Elderly*

The elderly have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2).

#### **Cardiovascular and cerebrovascular effects**

Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention, hypertension and oedema have been reported in association with NSAID therapy.

Clinical studies suggest that use of ibuprofen, particularly at a high dose (2400 mg/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low-dose ibuprofen (e.g.  $\leq$  1200 mg/day) is associated with an increased risk of arterial thrombotic events.

Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg/day) should be avoided.

Careful consideration should also be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses of ibuprofen (2400 mg/day) are required.

Cases of Kounis syndrome have been reported in patients treated with ibuprofen. Kounis syndrome has been defined as cardiovascular symptoms secondary to an allergic or hypersensitive reaction associated with constriction of coronary arteries and potentially leading to myocardial infarction.

#### **Renal effects**

Caution should be exercised with regard to use in patients with dehydration. There is a risk of renal impairment in dehydrated children, adolescents and the elderly.

Ibuprofen may cause the retention of sodium, potassium and fluid in patients who have not previously suffered from renal disorders because of its effect on renal perfusion. This may cause oedema or even lead to cardiac insufficiency or hypertension in predisposed patients.

As with other NSAIDs, the prolonged administration of ibuprofen to animals has resulted in renal papillary necrosis and other pathological renal changes. In humans, there have been reports of acute interstitial nephritis with haematuria, proteinuria and occasionally nephrotic syndrome. Cases of renal toxicity have also been observed in patients in whom prostaglandins play a compensatory role in the maintenance of renal perfusion. In these patients, administration of NSAIDs may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of suffering this reaction are those with renal dysfunction, heart failure, hepatic dysfunction, those taking diuretics and ACE inhibitors and the elderly. Discontinuation of NSAID treatment is generally followed by recovery to the pre-treatment state.

#### **Respiratory disorders**

Bronchospasm, urticaria or angioedema may be precipitated in patients suffering from or with a previous history of bronchial asthma, chronic rhinitis, sinusitis, nasal polyps, adenoids or allergic diseases.

Asthmatic patients are to seek their doctor's advice before using ibuprofen (see below).

**Severe cutaneous adverse reactions (SCARs)**

Severe cutaneous adverse reactions (SCARs) including exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome) and acute generalized exanthematous pustulosis (AGEP), which can be life-threatening or fatal, have been reported in association with the use of ibuprofen (see section 4.8). Most of these reactions occurred within the first month.

If signs and symptoms suggestive of these reactions appear ibuprofen should be withdrawn immediately and an alternative treatment considered (as appropriate).

**Masking of symptoms of underlying infections**

Ibuprofen can mask symptoms of infection, which may lead to delayed initiation of appropriate treatment and thereby worsening the outcome of the infection. This has been observed in bacterial community acquired pneumonia and bacterial complications to varicella. When ibuprofen is administered for fever or pain relief in relation to infection, monitoring of infection is advised. In non-hospital settings, the patient should consult a doctor if symptoms persist or worsen.

Exceptionally, varicella can be at the origin of serious cutaneous and soft tissue infectious complications. To date, the contributing role of NSAIDs in the worsening of these infections cannot be ruled out. Thus, it is advisable to avoid use of ibuprofen in case of varicella.

**Aseptic meningitis**

Symptoms of aseptic meningitis, such as stiff neck, headache, nausea, vomiting, fever or disorientation have been observed. Aseptic meningitis has been observed on rare occasions in patients on ibuprofen therapy. Although it is probably more likely to occur in patients with systemic lupus erythematosus (SLE) and related connective tissue diseases, it has been reported in patients who do not have an underlying chronic disease.

**Other precautions**

During the long-term, high-dose use of analgesics headaches may occur which should not be treated with elevated doses of the medicinal product.

In general the habitual intake of analgesics, particularly the combination use of different analgesic substances, may cause permanent renal damage and a risk of renal failure (analgesics nephropathy).

Ibuprofen may temporarily inhibit platelet aggregation and prolong the bleeding time. Therefore, patients with coagulation defects or on anticoagulant therapy should be observed carefully.

In case of long-term treatment with ibuprofen a periodical monitoring of hepatic and renal function as well as the blood count is necessary, especially in high risk patients.

Consumption of alcohol should be avoided since it may intensify side effects of NSAIDs, especially if affecting the gastrointestinal tract or the central nervous system.

**Paediatric population**

This medicine should not be given to children younger than 12 years.

**Excipient**

This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially 'sodium-free'.

**4.5 Interaction with other medicinal products and other forms of interaction*****The following combinations with ibuprofen should be avoided:***

**Acetylsalicylic acid:** Concomitant administration of ibuprofen and acetylsalicylic acid is not generally recommended because of the potential of increased adverse events.

Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. Although there are uncertainties regarding extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 5.1).

**Other NSAIDs:** As a result of synergistic effects, the concurrent use of several NSAIDs can increase the risk of gastrointestinal ulcers and haemorrhage. Co-administration of ibuprofen with other NSAIDs should therefore be avoided (see section 4.4).

*Anti-coagulants:* NSAIDs may enhance the effects of anticoagulants, such as warfarin or heparin (see section 4.4). In case of simultaneous treatment, monitoring of the coagulation state is recommended.

*Antiplatelet agents (Ticlopidine, Clopidogrel):* NSAIDs should not be combined with antiplatelet agents due to a risk of an additive effect in the inhibition of the platelet function. The risk of gastrointestinal bleeding is increased.

*Methotrexate:* NSAID inhibits the tubular secretion of methotrexate and certain metabolic interactions can occur resulting in decreased clearance of methotrexate. The administration of ibuprofen within 24 hours before or after the administration of methotrexate can lead to an elevated concentration of methotrexate and an increase in its toxic effects. Therefore, concomitant use of NSAIDs and high doses of methotrexate should be avoided. Also, the potential risk of interactions in low dose treatment with methotrexate should be considered, especially in patients with impaired renal function. In combined treatment, renal function should be monitored.

*Cardiac glycosides (e.g digoxin):* NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma levels of cardiac glycosides. Monitoring of serum digoxin is recommended.

*Mifepristone:* The efficacy of mifepristone may be decreased.

*Sulphonylureas:* NSAIDs can increase the hypoglycemic effect of sulphonylureas. In the case of simultaneous treatment, monitoring of blood glucose levels is recommended.

*Zidovudine:* There is evidence of an increased risk of haemarthrosis and haematoma in HIV positive haemophilia patients receiving concurrent treatment with zidovudine and ibuprofen. There may be an increased risk of haematotoxicity during concomitant use of zidovudine and NSAIDs. Blood counts 1- 2 weeks after starting use together are recommended.

***Ibuprofen should be taken only with caution in combination with the following substances:***

*Phenytoin, lithium:* Co-administration of ibuprofen with phenytoin or lithium preparations can increase the serum level of these medicinal products. Checking the serum lithium level is necessary and it is recommended to check the serum phenytoin levels.

*Diuretics and antihypertensives:* Diuretics and ACE-inhibitors can increase the nephrotoxicity of NSAIDs. NSAIDs can reduce the effect of diuretics and antihypertensives, including ACE-inhibitors and beta-blockers. In patients with reduced kidney function (e.g. dehydrated patients or elderly patients with reduced kidney function), the concomitant use of an ACE inhibitor and angiotension II antagonist with a cyclooxygenase-inhibiting medicinal product can lead to further impairment of kidney function and through to acute renal failure. This is usually reversible. Such combination should therefore only be used with caution, especially in elderly patients. The patients have to be instructed to drink sufficient liquid and periodic monitoring of the kidney values should be considered for the time immediately after the start of the combination therapy. The concomitant administration of ibuprofen and potassium-sparing diuretics or ACE-inhibitors can result in hyperkalaemia. Careful monitoring of potassium levels is necessary.

*Aminoglycosides:* NSAIDs can slow down the elimination of aminoglycosides and increase their toxicity.

*Selective serotonin reuptake inhibitors (SSRIs):* Increased risk of gastrointestinal bleeding (see section 4.4).

*Ciclosporin:* The risk of kidney damage by ciclosporin is increased by the concomitant administration of certain NSAIDs. This effect cannot be ruled out for the combination of ciclosporin and ibuprofen, either.

*Cholestyramine:* Concomitant treatment with cholestyramine and ibuprofen results in prolonged and reduced (25%) absorption of ibuprofen. The medicinal products should be administered with at least one hour interval.

*Tacrolimus:* Elevated risk of nephrotoxicity due to decreased synthesis of prostacyclin in the kidney. Accordingly, in the event of combination treatment, renal function should be monitored closely.

*Probenecid or sulfinpyrazone:* May cause a delay in the elimination of ibuprofen. The uricosuric action of these substances is decreased.

*Quinolone antibiotics:* Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions.

*Corticosteroids:* Increased risk of gastrointestinal ulceration or bleeding (see section 4.4).

*CYP2C9 Inhibitors:*

Concomitant administration of ibuprofen with CYP2C9 inhibitors may increase the exposure to ibuprofen (CYP2C9 substrate). In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased S(+)-ibuprofen exposure by approximately 80 to 100% has been shown. Reduction of the ibuprofen dose should be considered when potent CYP2C9 inhibitors are administered concomitantly, particularly when high-dose ibuprofen is administered with either voriconazole or fluconazole.

*Alcohol:* May potentiate the GI side-effects and the risk of bleeding and ulceration.

#### **4.6 Fertility, pregnancy and lactation**

*Pregnancy*

Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post- implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.

From the 20th week of pregnancy onward, ibuprofen use may cause oligohydramnios resulting from foetal renal dysfunction. This may occur shortly after treatment initiation and is usually reversible upon discontinuation. In addition, there have been reports of ductus arteriosus constriction following treatment in the second trimester, most of which resolved after treatment cessation. Therefore, during the first and second trimester of pregnancy, ibuprofen should not be given unless clearly necessary. If ibuprofen is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. Antenatal monitoring for oligohydramnios and ductus arteriosus constriction should be considered after exposure to ibuprofen for several days from gestational week 20 onward. Ibuprofen should be discontinued if oligohydramnios or ductus arteriosus constriction are found.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:

- cardiopulmonary toxicity (premature constriction/closure of the ductus arteriosus and pulmonary hypertension);
- renal dysfunction, (see above);

the mother and the neonate, at the end of pregnancy, to:

- possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses;
- inhibition of uterine contractions resulting in delayed or prolonged labour.

Consequently ibuprofen is contraindicated during the third trimester of pregnancy (see sections 4.3 and 5.3).

*Lactation*

Ibuprofen is excreted in breast milk, but with therapeutic doses during short term treatment the risk for influence on infant seems unlikely. If, however, longer treatment is prescribed, early weaning should be considered.

*Fertility*

The use of ibuprofen may impair fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of ibuprofen should be considered.

#### **4.7 Effects on ability to drive and use machines**

Following treatment with ibuprofen, the reaction time of certain patients may be affected since at high dosage side effects such as fatigue, somnolence, vertigo and visual disturbances may be experienced. This should be taken into account where increased vigilance is required, e.g. when driving a car. This applies to a greater extent in combination with alcohol.

#### **4.8 Undesirable effects**

The most commonly observed adverse events are gastrointestinal in nature. Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's

disease (see section 4.4) have been reported following administration. Less frequently, gastritis, gastric ulcers, duodenal ulcers and gastrointestinal perforation have been observed.

Gastrointestinal ulcers, perforation or bleeding may sometimes be fatal, especially in elderly persons (see section 4.4)

Undesirable effects are mostly dose-dependent. Especially the risk for the occurrence of gastrointestinal bleedings depends on the dosage range and duration of the treatment. Other known risk factors, see section 4.4.

Clinical studies suggest that use of ibuprofen, particularly at a high dose (2400 mg/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).

Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment.

Adverse events possibly related to ibuprofen are displayed by MedDRA frequency convention and system organ class database. The following frequency groupings are used:

Very common ( $\geq 1/10$ )

Common ( $\geq 1/100$  to  $< 1/10$ )

Uncommon ( $\geq 1/1,000$  to  $< 1/100$ )

Rare ( $\geq 1/10,000$  to  $< 1/1,000$ )

Very rare ( $< 1/10,000$ )

Not known (cannot be estimated from the available data).

### ***Infections and Infestations***

*Uncommon:*

*rhinitis*

*Rare*

*aseptic meningitis*

### ***Blood and lymphatic system disorders***

*Uncommon:*

haematopoietic disorders (anaemia, leucopenia, thrombocytopenia, neutropenia, pancytopenia, agranulocytosis, aplastic anaemia, haemolytic anaemia).

### ***Immune system disorders***

*Uncommon:*

hypersensitivity

*Rare:*

anaphylactic reaction (severe hypersensitivity reactions: tachycardia, fall of blood pressure to the point of life-threatening shock).

### ***Psychiatric disorders***

*Uncommon:*

anxiety

*Rare:*

depression, confusion, hallucinations

### ***Nervous system disorders***

*Common:*

headache, fatigue, dizziness, agitation, insomnia, irritability

*Uncommon:*

paraesthesia, somnolence

*Rare:*

optic neuritis

### ***Eye disorders***

*Uncommon:*

visual disturbances

*Rare:*

toxic optic neuropathy

***Ear and labyrinth disorders***

*Uncommon* hearing impaired

*Rare:* tinnitus, vertigo

***Cardiac disorders***

*Very rare:*

palpitations, heart failure, myocardial infarction, acute pulmonary oedema

*Not known*

*Kounis syndrome*

***Vascular disorder***

*Very rare:*

hypertension

***Respiratory, thoracic and mediastinal disorders***

*Uncommon:*

asthma, bronchospasm, dyspnoea

***Gastrointestinal disorders***

*Common:*

gastrointestinal disorders, such as heartburn, dyspepsia, abdominal pain and nausea, vomiting, flatulence, diarrhoea, constipation

gastrointestinal ulcers, sometimes with bleeding and perforation (see section 4.4), occult blood loss which may lead to anaemia, melaena, haematemesis, colitis, exacerbation of inflammatory bowel disease, complications of colonic diverticula (perforation, fistula)

*Uncommon:*

gastritis, ulcerative stomatitis

*Very rare:*

oesophagitis, pancreatitis, intestinal strictures.

***Hepatobiliary disorders***

*Very rare:*

liver dysfunction, liver damage, especially in long-term use, liver failure, acute hepatitis, jaundice

***Skin and subcutaneous tissue disorders***

*Common:*

rash

*Uncommon:*

photosensitivity reactions, urticaria, pruritus, purpura

*Very rare:*

severe cutaneous adverse reactions (SCARs), (including erythema multiforme, exfoliative dermatitis, exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, alopecia, necrotising fasciitis)

*Not known:*

drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), acute generalised exanthematous pustulosis (AGEP)

***Renal and urinary disorders***

*Uncommon:*

development of oedema especially in patients with arterial hypertension or renal insufficiency, nephrotic syndrome, interstitial nephritis which can be associated with renal failure

*Very rare:*

renal papillary necrosis in long-term use (see section 4.4)

### **General disorders and administration site conditions**

*Not known:*

malaise

### **Investigations**

*Rare:*

increase of blood urea nitrogen, serum transaminases and alkaline phosphatase, decrease in haemoglobin and haematocrit values, inhibition of platelet aggregation, prolonged bleeding time, decrease of serum calcium, increase in serum uric acid

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance Website: [www.hpra.ie](http://www.hpra.ie).

## **4.9 Overdose**

### *Symptoms*

Most patients who have ingested clinically important amounts of NSAIDs will develop no more than nausea, vomiting, epigastric pain, or more rarely, diarrhoea. Tinnitus, headache, dizziness, vertigo and gastrointestinal bleeding may also occur. In more serious poisoning, toxicity is seen in the central nervous system, manifesting as drowsiness, occasionally excitation and disorientation or coma. Occasionally patients develop convulsions. Children may also develop myoclonic cramps. In serious poisoning metabolic acidosis may occur and the prothrombin time/INR may be prolonged, probably due to the actions of circulating clotting factors. Acute renal failure, liver damage, hypotension, respiratory depression and cyanosis may occur. Exacerbation of asthma is possible in asthmatics.

### *Treatment*

Treatment should be symptomatic and supportive and include the maintenance of a clear airway and monitoring of cardiac and vital signs until stable. Gastric emptying or oral administration of activated charcoal is indicated if the patient presents within one hour of ingestion of more than 400 mg per kg of body weight. If ibuprofen has already been absorbed, alkaline substances should be administered to promote the excretion of the acid ibuprofen in the urine. If frequent or prolonged, convulsions should be treated with intravenous diazepam or lorazepam. Bronchodilators should be given for asthma. No specific antidote is available.

## **5 PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids; propionic acid derivatives. ATC code: M01AE01

Ibuprofen is a NSAID that possesses anti-inflammatory, analgesic and antipyretic activity. Animal models for pain and inflammation indicate that ibuprofen effectively inhibits the synthesis of prostaglandins. In humans, ibuprofen reduces pain possibly caused by inflammation or connected with it, swelling and fever. Ibuprofen exerts an inhibitory effect on prostaglandin synthesis by inhibiting the activity of cyclo-oxygenase. In addition ibuprofen has an inhibitory effect on ADP (adenosine diphosphate) or collagen-stimulated platelet aggregation.

Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. Some pharmacodynamics studies show that when single doses of ibuprofen 400 mg were taken within 8 h before or within 30 min after immediate release acetylsalicylic acid dosing (81 mg), a decreased effect of acetylsalicylic acid on the formation of thromboxane or platelet aggregation occurred. Although there are uncertainties regarding extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 4.5).

Ibuprofen inhibits prostaglandin synthesis in the uterus, thereby reducing intrauterine rest and active pressure, the periodic uterine contractions and the amount of prostaglandins released into the circulation. These changes are assumed to explain the alleviation of menstrual pain. Ibuprofen inhibits renal prostaglandin synthesis which can lead to renal insufficiency, fluid retention and heart failure in risk patients (see section 4.3).

Prostaglandins are connected with ovulation and the use of medicinal products inhibiting prostaglandin synthesis may therefore affect the fertility of women (see section 4.4, 4.6 and 5.3).

## 5.2 Pharmacokinetic properties

### *Absorption*

Ibuprofen is rapidly absorbed from the gastrointestinal tract, peak serum concentrations occurring 1-2 hours after administration.

### *Distribution*

Ibuprofen is rapidly distributed throughout the whole body. The plasma protein binding is approximately 99%.

### *Biotransformation*

Ibuprofen is metabolised in the liver (hydroxylation, carboxylation).

### *Elimination*

The elimination half-life is approximately 2.5 hours in healthy individuals. Pharmacologically inactive metabolites are mainly excreted (90%) by the kidneys but also in bile.

## 5.3 Preclinical safety data

As a well established and widely used product, the pre-clinical safety of ibuprofen is well documented.

Ibuprofen's subchronic and chronic toxicity was mainly shown by animal tests as gastric tract damage and ulcers.

The vitro and in vivo tests have not shown any clinically significant signs about ibuprofen's mutagenicity. Furthermore no carcinogenic effects have been observed in mice and rats.

Ibuprofen inhibits ovulation in rabbits and impairs implantation in various animal species (rabbit, rat, and mouse). In reproduction tests undertaken with rats and rabbits, ibuprofen passed across the placenta. When using doses toxic to the mother, malformations occur more frequently (i.e. ventricular septum defects).

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

#### *Tablet core*

Cellulose, microcrystalline

Silica, colloidal anhydrous

Hydroxypropylcellulose

Sodium laurylsulfate

Croscarmellose sodium

Talc

#### *Film coating (Opadry (white) 06B28499)*

Hypromellose

Macrogol 400

Titanium dioxide (E171).

### 6.2 Incompatibilities

Not applicable.

### **6.3 Shelf life**

3 years.

### **6.4 Special precautions for storage**

This medicinal product does not require any special storage conditions.

### **6.5 Nature and contents of container**

Opaque PVC/Aluminium blister packs.

Clear PVC/Aluminium blister packs.

Tablet containers (HDPE) with polypropylene caps.

*Pack sizes:*

Blisters: 6, 10, 12, 20, 24, 30, 50, 60, 90, 100 and 250 film-coated tablets.

Tablet containers: 10, 20, 30, 50, 100 and 250 film-coated tablets.

Not all pack sizes may be marketed.

### **6.6 Special precautions for disposal and other handling**

No special requirements.

## **7 MARKETING AUTHORISATION HOLDER**

Teva B.V.  
Swensweg 5  
2031GA Haarlem  
Netherlands

## **8 MARKETING AUTHORISATION NUMBER**

PA1986/117/003

## **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 3<sup>rd</sup> July 2009

Date of last renewal: 22<sup>nd</sup> March 2014

## **10 DATE OF REVISION OF THE TEXT**

March 2024